



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Adcirca™

**Common Name:** Tadalafil

**PDL Category:** Pulmonary Anti-Hypertensives

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Revatio®	Preferred

**Summary**

**Indications and Usage:** Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability.<sup>1</sup>

**Mechanism of Action:** Inhibits phosphodiesterase type 5 (PDE5) which increases concentrations of cyclic guanosine monophosphate (cGMP) resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed.<sup>1</sup>

**Dosage Forms:** Tablets: 20mg

**Recommended Dosage:** 40mg once daily with or without food.<sup>1</sup>

**Common Adverse Drug Reactions:** Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia, nasal congestion.<sup>1</sup>

**Contraindications:** Concomitant use of organic nitrates.<sup>1</sup>

**Manufacturer:** Eli Lilly and Company

**Analysis:** Adcirca™ is a new once daily PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. In the trial used to gain FDA approval, Adcirca™ was compared only to placebo, with the primary endpoint of an improved six-minute walk distance. Patients taking only Adcirca 40mg experienced a 44 meter improvement in six-minute walk distance compared to the placebo group. In a similar trial with Revatio™, patients experienced a mean increase in walk distance of 45-50 meters with all doses. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Adcirca™ be added to the Preferred Drug List as a non-preferred drug with conditions.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug with Conditions	

1. Adcirca™ [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.